Approval · Notice of Compliance 10536 · 2009
SIMVASTATIN TABLETS: Notice of Compliance 10536
Issued August 24, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10536
- Date
- August 24, 2009
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASTATIN TABLETS | 02331969 | Cancelled Pre Market |
| SIMVASTATIN TABLETS | 02331985 | Cancelled Pre Market |
| SIMVASTATIN TABLETS | 02332000 | Cancelled Pre Market |
| SIMVASTATIN TABLETS | 02332019 | Cancelled Pre Market |
| SIMVASTATIN TABLETS | 02331993 | Cancelled Pre Market |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB
- SIMVASTATIN 20 MG per TAB